FLT3 and acute myeloid leukemia: In vitro experiments conducted in MOLM-14, an AML cell line with FLT3-ITD, where either mutant RAS or FLT3-F691L was transduced into the parental cells and gilteritinib was administered at low/high-dose (25 and 250 nmol/L), suggested that the RAS-mutant clones were more likely selected by the high concentration of the inhibitor, besides the FLT3-F691L which was more likely to be selected by a low one.